logo
Plus   Neg
Share
Email

Genentech's Late-stage Study On Pemphigus Vulgaris Meets Primary Endpoint

Genentech, a member of the Roche Group (RHHBY), reported that late-stage PEMPHIX study showed its Rituxan or rituximab superior to Mycophenolate Mofetil in patients with pemphigus vulgaris.

The study met the primary endpoint at week 52, with 40.3% of patients treated with Rituxan achieving sustained complete remission (CR) without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the mycophenolate mofetil arm. All secondary endpoints were statistically significant in favor of Rituxan.

"The PEMPHIX study showed that 40% of people in the study could achieve complete remission from painful blistering without the need for corticosteroids for 16 weeks or more and that Rituxan may be a superior treatment option to mycophenolate mofetil," said Levi Garraway, chief medical officer and head of Global Product Development.

Pemphigus vulgaris is a rare, serious and potentially life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes. Mycophenolate Mofetilis an unapproved, commonly used treatment for Pemphigus vulgaris that is recommended in published treatment guidelines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Panera Bread Co. is launching a new subscription program that will allow customers to drink unlimited coffee and tea. The new program of $8.99 per month launches Thursday and covers hot coffee, iced coffee and hot tea. With the introduction of the subscription, Panera becomes the first national restaurant company to offer unlimited hot drip coffee, iced coffee and hot tea for $8.99 per month. Best Buy Co. Inc. (BBY) Thursday reported a fourth-quarter profit that increased 1.4 percent from last year, while, J. C. Penney Co.'s (JCP) quarterly profit dropped 64 percent. However, the results of the companies topped analysts' estimates. Safavieh LLC recalled about 760 units of Aura and Silas 3-Drawer Chests for possible serious tip-over and entrapment hazards that can result in death or injuries to children, the U.S. Consumer Product Safety Commission said in a statement. The company said the chests are unstable if they are not anchored to the wall.
Follow RTT
>